Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The mRNA Writing On The Wall, GSK Expands CureVac Alliance Into Next-Gen COVID-19 Vaccines

Includes 100m Dose Boost To CureVac's COVID-19 Manufacturing

Executive Summary

After major setbacks to its existing COVID-19 vaccine platform, GSK is expanding its presence in mRNA, which increasingly looks to be the future.

You may also be interested in...



Novartis Teams Up With CureVac To Make COVID-19 Vaccine

The Swiss major, which is already signed up to help produce Pfizer and BioNTech's COVID-19 vaccine, is offering its services to CureVac to produce its mRNA vaccine.

After COVID-19 Vaccine Setbacks, GSK Expands Vir Antibody Pact

The agreement focuses on respiratory viruses, especially influenza, and includes a $225m upfront payment plus an increase in GSK’s equity investment in Vir.

EMA Starts Rolling Review Of CureVac’s COVID-19 Vaccine

CureVac has submitted the pre-clinical data package for its COVID-19 vaccine to the European Medicines Agency, which will be reviewing the data on a rolling basis. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel